読み込み中
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
前日終値
$165.69
+$4.40 · +2.73%
日中の時刻はETです。市場データは遅延する場合があります。
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
日中レンジ
現在 $165.69
52週レンジ
現在 $165.69
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
58
適正価値
センチメント
60
まちまち
リスク
33
中程度のリスク
モメンタム
72
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
日中レンジ
現在 $165.69
52週レンジ
現在 $165.69
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 5.07億 USD | 3.83億 USD | 3.15億 USD | 2.83億 USD | 2.94億 USD |
| 売上原価 | 1.14億 USD | 9402.7万 USD | 7557.5万 USD | 6897.9万 USD | 6662.7万 USD |
| 粗利益 | 3.93億 USD | 2.89億 USD | 2.39億 USD | 2.14億 USD | 2.27億 USD |
| 研究開発 | 1.51億 USD | 1.36億 USD | 1.39億 USD | 1.23億 USD | 1.01億 USD |
| 販売・一般管理 | 3.29億 USD | 2.63億 USD | 2.24億 USD | 1.93億 USD | 1.79億 USD |
| 営業費用 | 4.8億 USD | 4.12億 USD | 3.68億 USD | 2.96億 USD | 2.6億 USD |
| 受取利息 | 1071.4万 USD | 1110.5万 USD | 916.4万 USD | 237.5万 USD | 128.8万 USD |
| 支払利息 | 463.5万 USD | 1004万 USD | 1363.3万 USD | 1372万 USD | 1337.2万 USD |
| 減価償却費と償却費 | 4234.5万 USD | 3992.2万 USD | 3797.8万 USD | 3594.6万 USD | 3442.1万 USD |
| 営業利益 | −8673.3万 USD | −1.22億 USD | −1.29億 USD | −8231.3万 USD | −3287.2万 USD |
| 純利益 | −1.88億 USD | −1.46億 USD | −1.35億 USD | −9919.5万 USD | −4959.3万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$192.89
上昇余地（16.42%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI3.18億0.01%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM2.45億0.31%787.4億 USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB2.31億0.12%1853億 USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK1.32億0.29%447億 USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF1.23億0.13%954億 USD0.05%$235+0.80%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM8740.91万0.55%158.4億 USD0.03%$53.45+0.17%
iShares Russell 2000 Growth ETFIWO8592.11万0.62%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO5952.83万0.32%180億 USD0.06%$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
